Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial (2019)
- Authors:
- Autor USP: NAHAS, WILLIAM CARLOS - FM
- Unidade: FM
- DOI: 10.1016/S1470-2045(18)30860-X
- Subjects: NEOPLASIAS PROSTÁTICAS; METÁSTASE NEOPLÁSICA; NEOPLASIAS ÓSSEAS; ESTEROIDES; ANDRÓGENOS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Lancet oncology
- ISSN: 1470-2045
- Volume/Número/Paginação/Ano: v. 20, n. 3, p. 408-419, 2019
- Status:
- Artigo possui versão em acesso aberto em repositório (Green Open Access)
- Versão do Documento:
- Versão submetida (Pré-print)
- Acessar versão aberta:
-
ABNT
SMITH, Matthew et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology, v. 20, n. 3, p. 408-419, 2019Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(18)30860-X. Acesso em: 09 abr. 2026. -
APA
Smith, M., Parker, C., Saad, F., Miller, K., Tombal, B., Ng, Q. S., et al. (2019). Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology, 20( 3), 408-419. doi:10.1016/S1470-2045(18)30860-X -
NLM
Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Nahas WC. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial [Internet]. Lancet oncology. 2019 ; 20( 3): 408-419.[citado 2026 abr. 09 ] Available from: https://doi.org/10.1016/S1470-2045(18)30860-X -
Vancouver
Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Nahas WC. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial [Internet]. Lancet oncology. 2019 ; 20( 3): 408-419.[citado 2026 abr. 09 ] Available from: https://doi.org/10.1016/S1470-2045(18)30860-X - COVID-19 among kidney-transplant recipients requiring hospitalization. [Carta]: preliminary data and outcomes from a single-center in Brazil
- Oncologic Outcomes in Young Adults With Kidney Cancer Treated During the Targeted Therapy Era
- Case 297. [Editorial]
- Extended vs limited pelvic lymphadenectomy during radical prostatectomy for intermediate- and high-risk prostate cancer: a prospective randomized trial
- Does the urinary tract infection caused by carbapenem-resistant Gram-negative bacilli impact the outcome of kidney transplant recipients?
- Robot-assisted laparoscopic radical prostatectomy with early retrograde release of the neurovascular bundle and endopelvic fascia sparing
- Intraoperative computed tomography for detection of residual stones in endourology procedures: systematic review and meta-analysis
- Clinical features and outcomes of tuberculosis in kidney transplant recipients in Brazil: a report of the last decade
- Endoscopic combined intrarenal surgery: best practices and future perspectives
- Clinical Characteristics and Treatment Outcomes of Patients With Advanced Germ Cell Tumor Treated at a Tertiary Cancer Center in Brazil
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
